These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24614285)

  • 41. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
    Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C
    Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib.
    Xu R; Shen H; Guo R; Sun J; Gao W; Shu Y
    Biomed Pharmacother; 2012 Jul; 66(5):384-9. PubMed ID: 22560634
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
    Faber AC; Li D; Song Y; Liang MC; Yeap BY; Bronson RT; Lifshits E; Chen Z; Maira SM; García-Echeverría C; Wong KK; Engelman JA
    Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19503-8. PubMed ID: 19850869
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
    Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
    Tracy S; Mukohara T; Hansen M; Meyerson M; Johnson BE; Jänne PA
    Cancer Res; 2004 Oct; 64(20):7241-4. PubMed ID: 15492241
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
    Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
    Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.
    Heavey S; Cuffe S; Finn S; Young V; Ryan R; Nicholson S; Leonard N; McVeigh N; Barr M; O'Byrne K; Gately K
    Oncotarget; 2016 Nov; 7(48):79526-79543. PubMed ID: 27765909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis.
    Zou H; Li L; Garcia Carcedo I; Xu ZP; Monteiro M; Gu W
    Int J Nanomedicine; 2016; 11():1947-58. PubMed ID: 27226714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
    Acquaviva J; Smith DL; Sang J; Friedland JC; He S; Sequeira M; Zhang C; Wada Y; Proia DA
    Mol Cancer Ther; 2012 Dec; 11(12):2633-43. PubMed ID: 23012248
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia.
    Wong J; Welschinger R; Hewson J; Bradstock KF; Bendall LJ
    Oncotarget; 2014 Nov; 5(21):10460-72. PubMed ID: 25361005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer.
    Zhang J; Qu Z; Yao H; Sun L; Harata-Lee Y; Cui J; Aung TN; Liu X; You R; Wang W; Hai L; Adelson DL; Lin L
    Biomed Pharmacother; 2019 Oct; 118():109169. PubMed ID: 31310954
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.
    Okabe T; Okamoto I; Tsukioka S; Uchida J; Iwasa T; Yoshida T; Hatashita E; Yamada Y; Satoh T; Tamura K; Fukuoka M; Nakagawa K
    Mol Cancer Ther; 2008 Mar; 7(3):599-606. PubMed ID: 18347146
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells.
    Li H; Hu J; Wu S; Wang L; Cao X; Zhang X; Dai B; Cao M; Shao R; Zhang R; Majidi M; Ji L; Heymach JV; Wang M; Pan S; Minna J; Mehran RJ; Swisher SG; Roth JA; Fang B
    Oncotarget; 2016 Jan; 7(3):3548-58. PubMed ID: 26657290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
    Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
    Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.
    Zhang J; Kalyankrishna S; Wislez M; Thilaganathan N; Saigal B; Wei W; Ma L; Wistuba II; Johnson FM; Kurie JM
    Am J Pathol; 2007 Jan; 170(1):366-76. PubMed ID: 17200208
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway.
    Jin H; Jiang AY; Wang H; Cao Y; Wu Y; Jiang XF
    Mol Med Rep; 2017 Sep; 16(3):3475-3481. PubMed ID: 28713965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-Tumor Activity of Yuanhuacine by Regulating AMPK/mTOR Signaling Pathway and Actin Cytoskeleton Organization in Non-Small Cell Lung Cancer Cells.
    Kang JI; Hong JY; Lee HJ; Bae SY; Jung C; Park HJ; Lee SK
    PLoS One; 2015; 10(12):e0144368. PubMed ID: 26656173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effect of bufalin combined gefitinib on lung cancer H1975 cells and its mechanisms research].
    Kang XH; Gong YB; Wang LF; Wang ZQ; Deng HB; Zhao XZ; Wu J; Xu ZY
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Aug; 33(8):1081-5. PubMed ID: 24325059
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced antitumor activity of 3-bromopyruvate in combination with rapamycin in vivo and in vitro.
    Zhang Q; Pan J; Lubet RA; Komas SM; Kalyanaraman B; Wang Y; You M
    Cancer Prev Res (Phila); 2015 Apr; 8(4):318-26. PubMed ID: 25644152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.
    Chen B; Xu X; Luo J; Wang H; Zhou S
    PLoS One; 2015; 10(6):e0129663. PubMed ID: 26061184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.